A bstract. Previous studies of the insulin receptor in disease states have utilized primarily techniques of equilibrium binding and, to a limited extent structural, analysis. Though techniques have been developed to study receptor degradation in normal cells, they have not been applied to disease states. In the present study we have examined insulin receptor degradation rate in B lymphocytes that were obtained from peripheral blood of normal subjects and patients with several syndromes of extreme insulin resistance. B lymphocytes were established in culture from each patient's peripheral cells by transformation with Epstein-Barr virus. The insulin receptors were surface labeled using Na'251/lactoperoxidase and the cells were returned to incubate in growth media. After varying periods of incubation, aliquots of cells were solubilized and the cell content of labeled receptor subunits were measured by immunoprecipitation with anti-receptor antibodies and NaDodSO4/polyacrylamide gel electrophoresis. The fall in '251-insulin receptor content approximated a single exponential and was quantitated as receptor subunit half-life (t1/2). In cell lines from four patients in whom the number of insulin receptors was reduced by >90%, the rate of receptor loss was greater than normal (t112 equals 3.8 ±0.9 h vs. 6.5±1.2 h; mean±SD, P < 0
Introduction
Insulin resistance is an important etiologic factor in many disorders of carbohydrate metabolism (1) . The insulin receptor is an important locus for examining the nature of insulinresistant states in both animals and humans (1) (2) (3) . Insulin resistance may result from abnormalities of receptor regulation (3) , autoantibodies against the receptor (4), primary defects in the insulin binding component (5) (6) (7) (8) , and from a variety of defects in post-binding events (9) . In primary defects of the receptor, cultured cells, either fibroblasts (7, 8, 10) or lymphocytes (5, 6) , retain the in vivo receptor binding characteristics. This allows for direct studies of the receptor in vitro (5) (6) (7) (8) 10 ).
On the other hand, cultured cells from patients with extreme insulin resistance which resulted from autoantibodies directed against the insulin receptor (type B syndrome of extreme insulin resistance) (4) have normal binding in vitro and presumably normal insulin receptors (1 1) .
The important determinants of receptor concentration in any cell type are the rates of receptor synthesis and degradation. The degradation rate of the insulin receptor has been measured in cultured cells from human and animals sources (12) (13) (14) (15) (16) (17) (18) . However, degradation rates have not previously been measured in cells from patients with insulin resistance. In this study we have measured the degradation rates of insulin receptors in cultured lymphocytes from normal subjects: in three subgroups of patients with presumed genetic' or primary insulin resistance, in one group with low-normal insulin receptor concentration, in one group with absolutely low insulin receptor concentration, and in one patient with a normal concentration ofa qualitatively abnormal receptor. Finally, we have studied cultured cells from patients with a secondary cause for their insulin resistance, i.e., type B extreme insulin resistance (autoantibodies to the insulin receptor) (4).
Methods
Materials Na'251 and Triton X-100 were from New England Nuclear, Boston, MA; aprotinin, phenylmethylsulfonyl fluoride, and glucose oxidase (type V) were from Sigma Chemical Co., St. Louis, MO; lactoperoxidase was from Boehringer-Mannheim Biochemicals, Indianapolis, IN; staphylococcal protein A (pansorbin) was from Calbiochem-Behring Corp., San Diego, CA; and reagents from gel electrophoresis were from Bio-Rad Laboratories, Richmond, CA.
Patients. Blood was obtained from six normal subjects including one infant, from nine patients with various genetic syndromes of extreme insulin resistance, and from three subjects with autoantibodies to the insulin receptor (type B syndrome) ( Table I ). The patients were classified as normal or low insulin binders based on binding to their cultured lymphocytes. This classification was usually consistent with the binding to other cell types, but discrepancies do occur and have been discussed previously (5 previously shown that the extremely low binding patients have a decrease in receptor concentration (5, 6, 19, 20) . All studies were approved by the Human Studies Committee of the National Institute of Arthritis, Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD.
Establishment and growth of lymphoblastoid cell lines. Human lymphoblastoid cell lines that were prepared by infection of peripheral blood lymphocytes with Epstein-Barr virus (21, 22) were grown in RPMI 1640 medium that was enriched with 10% heat-inactivated fetal calf serum (Flow Laboratories, Inc., McLean, VA). These cells grow in suspension and have an insulin receptor concentration of 10-50,000 receptors/cell. For these two reasons they have been used for structural studies of the receptor. The cells have a doubling time of -24 h. At the time of these studies, all cell lines had undergone multiple (>50) doublings. Cells were grown until they achieved stationary growth phase (usually 1-2 X 10' cells/ml). The cells were then harvested by centrifugation and washed three times in phosphate-buffered saline.
Surface labeling ofNa'25I. The cells were iodinated according to a modification of the method described by Kasuga et al. (12) . In brief, the cells were suspended (2-4 X 107 cells/ml) in phosphate-buffered saline that was supplemented with glucose (20 mM), lactoperoxidase (25 iAg/ml), glucose oxidase (1,100 mU/ml), and Na'25I (50-100 MCi/ ml) at 250C for 30 min. After iodination, cells were washed three times in phosphate-buffered saline and returned to culture medium (2-4 X 106 cells/ml). After this labeling procedure, the viability of the cells, as assessed by trypan blue exclusion, was >90%. The cells remained viable and metabolically active for the duration of these studies.
Receptor solubilization. After various times in culture, the labeled cells were washed three times in phosphate-buffered saline and once in 0.1 M sodium phosphate buffer, pH 6.0, which contained 1% bovine serum albumin. The cells were (24) (Fig. 1) . The radioactivity in labeled bands was quantitated by excising the bands from gels and measuring radioactivity in an autogamma counter (Nuclear Chicago Co., Des Plaines, IL).
Anti-receptor antibody. IgG fractions were prepared from the serum of a patient (B-10) (23) with type B extreme insulin resistance and from normal serum by protein A affinity chromatography (25) . The final protein concentration of the IgG fraction that contained the antireceptor antibody was 3.5 mg/ml. Serum from patient (B-2) (4) with type B extreme insulin resistance was used directly in some studies. In previous studies (5, 6, 19) , we have shown that the ability of antireceptor antibodies to inhibit "2I-insulin binding to cultured lymphocytes from normal subjects and subjects with extreme insulin resistance (including three of the low binders studied here) was identical. This was in contrast to studies in fibroblasts where significant differences in the pattern of antibody inhibition of '25l-insulin binding to cells from the same subjects were observed (8) . The explanation for these differences is not clear, but may be related to the presence of growth factor receptors on the fibroblasts (20) . However, it seems unlikely that the results in this study are due to differences in antibody recognition among the subgroups studied.
Calculations. The regions of the polyacrylamide gels in which the insulin receptor subunits migrate contain two radioactive components:
the '25l-labeled insulin receptor ("specific"), as well as 125I not directly associated with the insulin receptor ("nonspecific"). We have estimated the "nonspecific" component of radioactivity by performing parallel nonimmune precipitation and excising the relevant region of the gel corresponding to the specific immunoprecipitates. In previous studies with IM-9 cells, this "nonspecific" component had been considered to be negligible (12) . However, in the present studies we found it necessary to correct for the "nonspecific" radioactivity for two reasons:
1. The cells that were studied here have fewer insulin receptors than IM-9 cells. Thus, the "specific" radioactivity was a smaller fraction of the total. 2. The use of an anti-receptor IgG (B-bI) with a lower anti-receptor activity necessitated the addition of more antibody to achieve immunoprecipitation. The increase in the concentration of IgG appeared to increase the amount of radioactivity nonspecifically trapped. In general, the "nonspecific" radioactivity was smaller in the 135,000-mol wt region than in the 95,000-mol wt region. For these reasons, the data for the 135,000-mol wt subunit with the nonspecific correction are presented in detail (Figs. 2-4) , and the uncorrected data for both the 135,000-and 95,000-mol wt subunits are summarized in Table II Despite this, the insulin receptor subunits could be identified (Fig. 1 B) and the half-lives quantitated (Fig. 3, A-D) . The degradation rate of the 135,000-mol wt subunits in these low binding cells was accelerated -40%, with a mean half-life of -3.8±0.9 h (P < 0.01 vs. normal control) (Fig. 4) .
To insure that overall protein turnover was not different among the cell lines studied, a nonspecific band of -55,000 mol wt present in all subjects was evaluated with respect to its 2. t1/2, receptor subunit half-life. turnover rate. No differences were found among the three groups studied (Table II) .
Degradation ofthe 135,000-mol wt subunit in patients with insulin resistance and low-normal '25I-insulin binding. In five of our insulin-resistant patients, cultured lymphocytes had a low normal number of insulin receptors. When receptor degradation was studied in cells from these five patients, the mean Table I ). Cells were processed as described in Fig. 1 Table I ), (C) type A insulin resistance (patient 12 in Table I) , and (D) leprechaunism (patient 13 in Table 1 ). 135K, 135,000 mol wt.
degradation rate of the 135,000-mol wt subunit was 4.4±0.9 h (P < 0.01 vs. normal controls) (Fig. 4) . Thus, insulin receptor degradation was faster than in normal cells but indistinguishable from cells of patients with unequivocal low binding (P >0.05) (Fig. 4) . One of the patients with a normal number of receptors has been shown to have a qualitatively abnormal receptor (28) . This receptor has a higher affinity than normal and the affinity is resistant to the changes that were induced by variations in pH, temperature, and purification over lectin columns (28) . The degradation rate of the 135,000-mol wt subunit of this abnormal receptor was 3.5±0.6 h (n = 3) (Fig.  2 B) (i.e., indistinguishable from other insulin-resistant patients with either normal or low insulin binding) (Fig. 4) .
Degradation ofthe 135,000-and 95,000-mol wt subunits-\ Cells from all the control subjects and patients were iodinated and processed as described in Fig. 1 . The autoradiographs of each subject were scanned densitometrically to determine the radioactivity associated with the nonspecifically immunoprecipitated protein of -55,00 mol wt at each time point. Linear regression was then performed to determine the half-life of the protein. (Table III) . This is true because the nonspecific component at all time points is a much higher proportion of the radioactivity in subjects with low binding and low receptor concentration. This is even a greater problem for the 95,000-mol wt subunit (Table III) . Thus, we do not feel that these uncorrected data are reliable but present them here for completeness. In previous studies using IM-9 lymphocytes, the turnover rates for the 135,000-and 95,000-mol wt components were similar, which suggested that degradation of the two receptor subunits occurs in parallel (12, 18) . The estimates of receptor turnover (especially for the 95,000-mol wt subunit) in those studies may have been more precise for technical reasons: IM-9 lymphocytes have more insulin receptors than do the cultured cells employed in these studies; and the use of a higher titer anti-receptor antiserum (B-2) in those studies led to a reduction in nonspecific immunoprecipitation. Degradation of the 135,000-mol wt subunit in cultured lymphocytes from patients with autoantibodies to the insulin receptor (type B syndrome). Until now we have discussed data that was derived from patients with intrinsic cellular abnormalities that may be expected to be retained in tissue culture. In order to establish further specificity for accelerated receptor degradation in these syndromes of extreme insulin resistance, we have studied three cell lines that were derived from patients who manifested extreme insulin resistance in vivo secondary to autoantibodies to the insulin receptor. Under these conditions, the insulin receptor is presumed to be normal when not associated with the autoantibody (11). '25I-insulin binding in these cell lines is in the low-normal range (Table IV) . Nevertheless, when the degradation of the 1 35,000-mol wt subunit was studied in these cells (Table IV) , it was indistinguishable from normal ( Fig. 4) and distinct from the accelerated degradation Cells from all the control subjects and patients were iodinated and processed as described in Fig. 1 . Individual half-lives for the 135,000-mol wt subunits were calculated as described in Fig.  2 . Each symbol (o) represents an individual study, and the number identifies the patient as in Table I . The half-lives are grouped according to the patient's classification with regard to receptor status. The horizontal lines show weighted means of each group. 135K, 135,000 mol wt.
enon in cells derived from the patients. Rates of insulin receptor degradation have been estimated in other cell types using a variety of methods (Table V) . It can be seen that the rates described in this paper are within the range of rates (12) (13) (14) (15) (16) (17) (18) . However, this is the first estimation of receptor turnover in cells from patients with insulin resistance; therefore, controls for these studies were cells cultured from normal subjects that were processed identically to the patients' cells.
The EBV-transformed lymphocytes (5, 6) used in this study preserve the insulin receptor phenotype (5) of these insulin-resistant patients. Moreover, these cells have certain features that facilitate the technical aspect of these studies: growth in suspension, a relatively large number of insulin receptors per cell, and the absence of receptors for insulinlike growth factor which might complicate interpretation of the results (5, 20) .
Receptor degradation is accelerated in patients with genetic syndromes of insulin resistance. The significance of modestly accelerated turnover of insulin receptors in cells from the patients with the genetic syndromes that cause insulin resistance is unclear. It is tempting to speculate, however, that it reflects an abnormality in the receptors of these patients. In the one patient with insulin resistance, normal receptor concentration, and a qualitatively abnormal receptor (28) , the half-lives of the 135,000-and 95,000-mol wt subunits were 3.5±0.6 and 3.4±0.7 (n = 3) h, respectively (Fig. 2 B) . It is possible that this qualitatively abnormal receptor is turned over rapidly because it is recognized by the cells as being abnormal, although the actual abnormality remains to be defined. Clearly, more sensitive methods will be necessary to detect these putative defects in other patients.
Mechanisms responsible for reduced cell surface receptor concentration. To maintain normal insulin receptor concentration in the face of increased degradation of the receptor, receptor synthesis must increase. In those cells with the low receptor concentration, this compensatory increase in receptor synthesis fails to occur. Further, in this subgroup, the reduction in receptor concentration is >90% as compared with normal. A 40% increase in the degradation rate does not account for the degree of receptor loss in the low binding subgroup and suggests a major defect in receptor synthesis. On the other hand, it is possible that, with unaltered receptor synthesis, an accelerated receptor degradation of -40% could account for the decreased binding in the low-normal subgroup of patients where binding is decreased to -50% of normal. However, the turnover rates of the receptor in patients with type B extreme insulin resistance (Table IV) suggest this is too simple an interpretation.
Production, or "synthesis", of the mature insulin receptor and its insertion in the plasma membrane is a complex, multistep process. The receptor consists of at least two complex glycoprotein subunits, which are derived from a single chain glycoprotein precursor (24) . Any abnormality in transcription, translation, or post-translational processing and packaging could result in a limited number of phenotypic receptor abnormalities as detected by receptor-binding studies. In the present study, the 135,000-and 95,000-mol wt subunits were identified in all subjects and were qualitatively normal. Further, 3T3-LI (14) Insulin binding/tunicamycin adipocytes [8] [9] [10] 3T3-LI ( (29) . Examples of post-translational "synthesis" defects have been identified for the low density lipoprotein (LDL) receptor in cultured fibroblasts. In that system, the normal mature LDL receptor is a 160,000-mol wt glycoprotein formed by post-translational modification of a 120,000-mol wt precursor. In family studies (30) of one patient with familial hypercholesterolemia due to a deficiency in the LDL binding sites, two abnormalities were uncovered. One was the failure to process the 120,000-mol wt precursor to the mature form and the other was an abnormally long 1 70,000-mol wt precursor processed to an abnormal 210,000-mol wt product. In these cases, LDL binding was low but receptor content as measured by anti-receptor antibody binding was normal. The majority of patients with familial hypercholesterolemia, as in our patients, have reduced receptor concentration as measured by ligand and antibody binding.
We have studied the degradation rates of insulin receptors from cultured cells of normal subjects and patients with genetic syndromes of extreme insulin resistance. We have found that these patients as a group have accelerated receptor degradation. By contrast, receptor degradation rates from cells studied in vitro from patients with a secondary cause of in vivo insulin resistance due to autoantibodies to the receptor are normal. The cause of this accelerated degradation is not known, but could relate to subtle receptor abnormalities that were not detected by binding or structural studies (1-3, 5, 6) .
